NRx Pharmaceuticals proposes public offering of common stock; terms not set

NRX Pharmaceuticals, Inc.

Intends to offer common stock in underwritten public offering; no size or price disclosed.
Underwriter granted 30-day option to purchase up to 15% additional shares on same terms.
BTIG is lead bookrunner; Lucid Capital Markets joint bookrunner for the offering.
Net proceeds to be used for working capital and general corporate purposes.
Offering under effective shelf registration statement (File No. 333-288205) declared effective Dec 22, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.